BALTIMORE, MD--(MARKET WIRE)--Dec 3, 2008 -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Easter District of Missouri on behalf of purchasers of KV Pharmaceutical Company ("KV" or the "Company") Class A Common Stock (NYSE:KV-A - News), Class B Common Stock (NYSE:KV-B - News) and 7% cumulative convertible Preferred Stock during the period between February 15, 2008 and November 12, 2008, inclusive (the "Class Period").

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than February 2, 2009 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You may contact Brower Piven (through hoffman@browerpiven.com or 410/986-0036) to answer any questions you may have in that regard.

The Complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the Company's failure to disclose during the Class Period that KV's manufacturing facilities were in disarray resulting in the manufacture of unsafe drug products that would have to be recalled, that manufacturing disruptions and inefficiencies were resulting in a material backlog of unshipped customer orders, thus further eroding the Company's revenues and earnings, and that KV's financial statements failed to comply with Generally Accepted Accounting Principles. According to the complaint, on November 13, 2008, after the Company revealed the previously undisclosed information and that its financial reporting for the quarter ended September 30, 2008 would be delayed, the value of KV's stock declined significantly.

If you have suffered a net loss for all transactions in KV Pharmaceutical Company Class A Common Stock, Class B Common Stock and/or 7% cumulative convertible Preferred Stock during the Class Period, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410-986-0036, or at Brower Piven, A Professional Corporation, The World Trade Center-Baltimore, 401 East Pratt Street, Suite 2525, Baltimore, Maryland 21202. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 40 years. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

     CONTACT:
     Charles J. Piven
     Brower Piven, A Professional Corporation
     Baltimore, Maryland
     410/986-0036
     Email Contact